Helping your therapies succeed

Regulatory requirements to commercialize cell therapy
Due to evolving science and unique properties of cell or tissue based products, GMP development and production for cell therapy products have been challenging, especially in clearly defining the quality attributes, and in defining what tools to use to achieve these quality attributes.

Clinical development of tumor-infiltrating lymphocyte therapy for solid tumors: The myths and the reality
Dr Laszlo Radvanyi, Ph.D, discusses common misconceptions about tumor-infiltrating lymphocyte therapy.

Targeting tumors with bi-specific antibody T cells
Dr Thakur presents her research on how non-MHC restricted cytotoxicity mediated by anti-CD3 activated T cells can be redirected by arming the cells with bi-specific antibody to target tumor associated antigens.

GMP considerations for adoptive cell transfer
Marco Donia, M.D., Ph.D., discusses what to consider when setting up a process to progress through GMP Production for adoptive cell transfer immunotherapy.